HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: A vast array of both natural and synthetic compounds acts as HDAC inhibitors.71 Two histone deacetylases inhibitors (HDACi), vorinostat and romidepsin, have been approved by FDA for the treatment against refractory cutaneous T-cell lymphoma (CTCL).